ENOVIS CORP (ENOV) Stock Fundamental Analysis
NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
ENOV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health. ENOV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
ENOV had a positive operating cash flow in the past year.
In multiple years ENOV reported negative net income over the last 5 years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV has a Return On Assets (-17.49%) which is in line with its industry peers.
ENOV's Return On Equity of -32.22% is in line compared to the rest of the industry. ENOV outperforms 57.14% of its industry peers.
ENOV's Return On Invested Capital of 0.23% is fine compared to the rest of the industry. ENOV outperforms 65.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.49% | ||
| ROE | -32.22% | ||
| ROIC | 0.23% |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENOV has a Operating Margin of 0.58%. This is in the better half of the industry: ENOV outperforms 65.61% of its industry peers.
In the last couple of years the Operating Margin of ENOV has declined.
The Gross Margin of ENOV (56.87%) is comparable to the rest of the industry.
ENOV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.87% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ENOV is destroying value.
Compared to 1 year ago, ENOV has more shares outstanding
The number of shares outstanding for ENOV has been increased compared to 5 years ago.
Compared to 1 year ago, ENOV has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.08, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
ENOV has a Altman-Z score (1.08) which is in line with its industry peers.
A Debt/Equity ratio of 0.51 indicates that ENOV is somewhat dependend on debt financing.
ENOV's Debt to Equity ratio of 0.51 is on the low side compared to the rest of the industry. ENOV is outperformed by 60.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.08 |
ROIC/WACC0.03
WACC8.68%
2.3 Liquidity
A Current Ratio of 2.17 indicates that ENOV has no problem at all paying its short term obligations.
With a Current ratio value of 2.17, ENOV is not doing good in the industry: 62.43% of the companies in the same industry are doing better.
ENOV has a Quick Ratio of 1.13. This is a normal value and indicates that ENOV is financially healthy and should not expect problems in meeting its short term obligations.
ENOV's Quick ratio of 1.13 is on the low side compared to the rest of the industry. ENOV is outperformed by 73.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.13 |
3. Growth
3.1 Past
ENOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.92%, which is quite good.
Measured over the past years, ENOV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.18% on average per year.
Looking at the last year, ENOV shows a very strong growth in Revenue. The Revenue has grown by 23.46%.
The Revenue has been decreasing by -8.73% on average over the past years.
EPS 1Y (TTM)17.92%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%24.05%
Revenue 1Y (TTM)23.46%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%23.29%
3.2 Future
ENOV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.19% yearly.
ENOV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.87% yearly.
EPS Next Y14.79%
EPS Next 2Y14.8%
EPS Next 3Y14.97%
EPS Next 5Y23.19%
Revenue Next Year5.32%
Revenue Next 2Y5.82%
Revenue Next 3Y6.17%
Revenue Next 5Y8.87%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 12.47, which indicates a correct valuation of ENOV.
Based on the Price/Earnings ratio, ENOV is valued cheaper than 91.53% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.22, ENOV is valued rather cheaply.
With a Price/Forward Earnings ratio of 10.87, the valuation of ENOV can be described as very reasonable.
Based on the Price/Forward Earnings ratio, ENOV is valued cheaper than 94.71% of the companies in the same industry.
ENOV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.47 | ||
| Fwd PE | 10.87 |
4.2 Price Multiples
88.36% of the companies in the same industry are more expensive than ENOV, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.97 |
4.3 Compensation for Growth
ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENOV's earnings are expected to grow with 14.97% in the coming years.
PEG (NY)0.84
PEG (5Y)N/A
EPS Next 2Y14.8%
EPS Next 3Y14.97%
5. Dividend
5.1 Amount
No dividends for ENOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
35.3
+0.7 (+2.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.11%
Inst Owner Change0.1%
Ins Owners0.96%
Ins Owner Change8.18%
Market Cap2.02B
Analysts83.53
Price Target66.43 (88.19%)
Short Float %10.43%
Short Ratio6.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.6%
Min EPS beat(2)4.97%
Max EPS beat(2)16.23%
EPS beat(4)4
Avg EPS beat(4)6.3%
Min EPS beat(4)1.38%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)7.78%
EPS beat(12)12
Avg EPS beat(12)9.15%
EPS beat(16)15
Avg EPS beat(16)7.61%
Revenue beat(2)0
Avg Revenue beat(2)-1.33%
Min Revenue beat(2)-1.74%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-1.09%
Min Revenue beat(4)-2.12%
Max Revenue beat(4)0.45%
Revenue beat(8)4
Avg Revenue beat(8)-0.47%
Revenue beat(12)5
Avg Revenue beat(12)-0.98%
Revenue beat(16)6
Avg Revenue beat(16)-12.25%
PT rev (1m)-0.57%
PT rev (3m)-1.33%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)13.27%
EPS NY rev (1m)0.03%
EPS NY rev (3m)1.32%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)2.62%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.47 | ||
| Fwd PE | 10.87 | ||
| P/S | 0.96 | ||
| P/FCF | N/A | ||
| P/OCF | 17.76 | ||
| P/B | 0.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.97 |
EPS(TTM)2.83
EY8.02%
EPS(NY)3.25
Fwd EY9.2%
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)1.99
OCFY5.63%
SpS36.9
BVpS44.87
TBVpS-7.84
PEG (NY)0.84
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.49% | ||
| ROE | -32.22% | ||
| ROCE | 0.29% | ||
| ROIC | 0.23% | ||
| ROICexc | 0.23% | ||
| ROICexgc | 0.85% | ||
| OM | 0.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.87% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.41 | ||
| Cap/Depr | 63.45% | ||
| Cap/Sales | 8.57% | ||
| Interest Coverage | 0.24 | ||
| Cash Conversion | 38.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 1.08 |
F-Score3
WACC8.68%
ROIC/WACC0.03
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.92%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%24.05%
EPS Next Y14.79%
EPS Next 2Y14.8%
EPS Next 3Y14.97%
EPS Next 5Y23.19%
Revenue 1Y (TTM)23.46%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%23.29%
Revenue Next Year5.32%
Revenue Next 2Y5.82%
Revenue Next 3Y6.17%
Revenue Next 5Y8.87%
EBIT growth 1Y-39.31%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year81.17%
EBIT Next 3Y30.6%
EBIT Next 5Y28.11%
FCF growth 1Y-626.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.92%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%